tbuckley/cabot-search huggingface dataset:
A big-data approach to producing descriptive anthropometric references: a feasibility and validation study of paediatric growth charts
Authors: Barbara Heude, Pauline Scherdel, Andreas Werner, Morgane Le Guern, Nathalie Gelbert, Déborah Walther, Michel Arnould, Marc Bellaïche, Bertrand Chevallier, Jacques Cheymol, Emmanuel Jobez, Sylvie N'Guyen, Christine Pietrement, Rachel Reynaud, Jean-François Salaün, Babak Khoshnood, Jennifer Zeitlin, Jean Maccario, Gérard Breart, Jean-Christophe Thalabard, Marie-Aline Charles, Jérémie Botton, Bruno Frandji, Martin Chalumeau
Journal: The Lancet Digital Health (2019)

Both national and WHO growth charts have been found to be poorly calibrated with the physical growth of children in many countries. We aimed to generate new national growth charts for French children in the context of huge datasets of physical growth measurements routinely collected by office-based health practitioners.We recruited 32 randomly sampled primary care paediatricians and ten volunteer general practitioners from across the French metropolitan territory who used the same electronic medical records software, from which we extracted all physical growth data for the paediatric patients, with anonymisation. We included measurements from all children born from Jan 1, 1990, and aged 1 month to 18 years by Feb 8, 2018, with birthweight greater than 2500 g, to which an automated process of data cleaning developed to detect and delete measurement or transcription errors was applied. Growth charts for weight and height were derived by using generalised additive models for location, scale, and shape with the Box-Cox power exponential distribution. We compared the new charts to WHO growth charts and existing French national growth charts, and validated our charts using growth data from recent national cross-sectional surveys.After data cleaning, we included 1 458 468 height and 1 690 340 weight measurements from 238 102 children. When compared with the existing French national and WHO growth charts, all height SD and weight percentile curves for the new growth charts were distinctly above those for the existing French national growth charts, as early as age 1 month, with an average difference of -0·75 SD for height and -0·50 SD for weight for both sexes. Comparison with national cross-sectional surveys showed satisfactory calibration, with generally good fit for children aged 5-6 years and 10-11 years in height and weight and small differences at age 14-15 years.We successfully produced calibrated paediatric growth charts by using a novel big-data approach applied to data routinely collected in clinical practice that could be used in many fields other than anthropometry.The French Ministry of Health; Laboratoires Guigoz-General Pediatrics section of the French Society of Pediatrics-Pediatric Epidemiological Research Group; and the French Association for Ambulatory Pediatrics.
Prevalence and Associated Factors for Arterial Hypertension in Adults Following Hematopoietic Stem Cell Transplantation
Authors: Claudia Marcela Chalela, Juan Carlos Uribe, Maria Luna-Gonzalez, Angela María Peña, Sara Ines Jimenez, Luis Antonio Salazar, Manuel Rosales, Manuel Ardila-Baez, Katherine Espinosa, Julian Baez, David Leonardo Reyes, Juan Jose Rey, Sergio Serrano, Jose Sandoval-Sus, Claudia Lucia Sossa
Journal: Blood (2019)
TMIC-33. INVESTIGATING S1PR3-MEDIATED GLIOBLASTOMA INVASION MECHANISMS USING 3D HYDROGEL - TISSUE CULTURE INSERT MODEL
Authors: Kinsley Tate, R Chase Cornelison, Saloni Bhargava, Jennifer Munson
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma (GBM) is the most common malignant brain tumor and is characterized by its ability to invade into the surrounding microenvironment of the brain. The invasiveness of GBM makes this cancer extremely hard to treat, leading to a median patient survival of less than 16 months. Interactions between the tumor and surrounding tumor microenvironment (TME) play a key role in glioma invasion. Previous data from our xenograft mouse tumor implant model displays increased invasion in regions of fluid flow. Using this model, we identified an upregulation of sphingosine-1-phosphate receptor 3 (S1PR3) in the TME in regions of flow. We used a syngeneic GL261 mouse model and found S1PR3-/- mice display decreased flow-mediated glioma invasion in comparison to wild type mice. To further understand the individual contributions of the S1PR3-presenting cells in the TME, we have examined the role of S1PR3 in our in vitro system. This system is based on patient derived cellular ratios and incorporates collagen-hyaluronan hydrogels placed within 96 well tissue culture insert plates. The tunability of this model allows for interactions between various cell types and the impact of fluid flow on invasion to be examined. To examine the role of S1PR3 on invasion, TY52156 (an S1PR3 inhibitor) was applied to different cellular combinations including: G34 alone (a patient-specific cell line), +astrocytes, +microglia, +TME (astrocytes and microglia). A significant decrease in G34 flow stimulated invasion was observed with TY52156 but only in the presence of the TME or microglia alone. This data suggests that TY52156 thwarts the effects of flow and the microglia contributions to invasion. To further this work we plan to identify and evaluate other S1PR3-expressing cell types from mouse tumor implant samples using immunohistochemistry staining. This information will be used to determine further components that can be examined in our in vitro model.
The Impact of Red Blood Cell Transfusion on Mortality and Treatment Efficacy in Patients Treated with Radiation: A Systematic Review of the Literature
Authors: Max Deschner, Sondos Zayed, Lakshman Vasanthamohan, Alejandro Lazo-Langner, David Palma, David D'Souza, Syed Omar Gilani, R. Gabriel Boldt, Ziad Solh
Journal: Blood (2019)
Clinical Clues in Virus Infections
Authors: C. D. Baker
Journal: BMJ (1963)

The emoluments for night doctors are worked out in some detail.Payment varies with the hour of the night.A visit at 2 a.m.carries a higher rate than one at 11 p.m. Doctors did not discourage night calls, for since three visits in one night is sufficent to ruin anyone's sleep, with small recompense, a sleepless night with 20 calls provides some compensation.I believe I am right in saying that this emergency system operates largely in Copenhagen itself, and that it has not proved entirely feasible to practise the same method in outlying districts.My opinion of the medical service as a whole in Denmark was that it was most excellent.No system which produced men of the calibre of Meulengracht could be otherwise.-Iam, etc., High Wycombe, Bucks.
CSIG-16. RECONCILING TUMOR HETEROGENEITY IN GLIOBLASTOMA USING A PATHWAY-BASED APPROACH
Authors: Alvaro Alvarado, Riki Kawaguchi, Giovanni Coppola, Steven Goldman, Harley Kornblum
Journal: Neuro-Oncology (2019)

Abstract Despite efforts to gain a deeper understanding of its molecular architecture, glioblastoma (GBM) remains uniformly fatal. While genome-based molecular subtyping has revealed that GBMs may be parsed into several distinct molecular categories, this insight has yielded little progress towards extending patient survival. In particular, the great phenotypic heterogeneity of GBM – both inter and intratumorally – has hindered therapeutic efforts. To this end, we interrogated tumor samples using a pathway-based approach to resolve tumoral heterogeneity. Gene set enrichment analysis (GSEA) was applied to gene expression data and used to provide an overview of each sample that was then compared to others, generating sample clusters based on overall patterns of enrichment. The Cancer Genome Atlas (TCGA) samples were clustered using canonical and oncogenic signatures and in both cases the clustering was distinct from the molecular subtypes previously reported. Using principal component analysis (PCA) and other bioinformatics tools, we extracted gene sets to further characterize the pathways contributing to each of these clusters. We generated gene lists of the top common elements and Ingenuity pathway analysis exposed molecular targets that control critical pathways of each identified cluster. Similar analyses were completed in a gene expression database of patient-derived gliomasphere lines and molecular targets were also obtained. We found E2F1 to be a strong target based on gene lists from both databases. A cluster of gliomasphere lines have high enrichment scores for the gene list predicted to depend on E2F1. In vitro genetic perturbation showed decrease stem cell frequency and lower expression of cell cycle progression genes in cell lines from this cluster exclusively. Other cluster-specific targets are being validated and in vivo studies will follow momentarily. Our studies relate intertumoral heterogeneity to critical cellular pathways dysregulated in GBM, with the ultimate goal of establishing a pipeline for patient- and tumor-specific precision medicine.
Association Between Polyp Detection Rate and Post-Colonoscopy Cancer Among Patients Undergoing Diagnostic Colonoscopy
Authors: Rachel Gingold-Belfer, Doron Boltin, Orly Sneh-Arbib, Doron Comaneshter, Arnon Cohen, Anath Flugelman, Alex Vilkin, Yaron Niv, Lital Boker Keinan, Iris Dotan, Zohar Levi
Journal: Clinical Gastroenterology and Hepatology (2019)
Organoid Cultures as Preclinical Models of Non–Small Cell Lung Cancer
Authors: Ruoshi Shi, Nikolina Radulovich, Christine Ng, Ni Liu, Hirotsugu Notsuda, Michael Cabanero, Sebastiao N. Martins-Filho, Vibha Raghavan, Quan Li, Arvind Singh Mer, Joshua C. Rosen, Ming Li, Yu-Hui Wang, Laura Tamblyn, Nhu-An Pham, Benjamin Haibe-Kains, Geoffrey Liu, Nadeem Moghal, Ming-Sound Tsao
Journal: Clinical Cancer Research (2019)

Abstract Purpose: Non–small cell lung cancer (NSCLC) is the most common cause of cancer-related deaths worldwide. There is an unmet need to develop novel clinically relevant models of NSCLC to accelerate identification of drug targets and our understanding of the disease. Experimental Design: Thirty surgically resected NSCLC primary patient tissue and 35 previously established patient-derived xenograft (PDX) models were processed for organoid culture establishment. Organoids were histologically and molecularly characterized by cytology and histology, exome sequencing, and RNA-sequencing analysis. Tumorigenicity was assessed through subcutaneous injection of organoids in NOD/SCID mice. Organoids were subjected to drug testing using EGFR, FGFR, and MEK-targeted therapies. Results: We have identified cell culture conditions favoring the establishment of short-term and long-term expansion of NSCLC organoids derived from primary lung patient and PDX tumor tissue. The NSCLC organoids recapitulated the histology of the patient and PDX tumor. They also retained tumorigenicity, as evidenced by cytologic features of malignancy, xenograft formation, preservation of mutations, copy number aberrations, and gene expression profiles between the organoid and matched parental tumor tissue by whole-exome and RNA sequencing. NSCLC organoid models also preserved the sensitivity of the matched parental tumor to targeted therapeutics, and could be used to validate or discover biomarker–drug combinations. Conclusions: Our panel of NSCLC organoids closely recapitulates the genomics and biology of patient tumors, and is a potential platform for drug testing and biomarker validation.
DDIS-36. BTP-7, A NOVEL PEPTIDE FOR THERAPEUTIC TARGETING OF MALIGNANT BRAIN TUMORS
Authors: Niklas von Spreckelsen, Yarah Ghotmi, Colin Fadzen, Justin Wolfe, Nina Hartrampf, Sonja Bergmann, Yuan Qu, Emily Murrell, Fernanda Bononi, Leonard Luyt, Martine Lamfers, Keith Ligon, Ennio Chiocca, Mariano Viapiano, Bradley L Pentelute, Sean Lawler, Choi-Fong Cho
Journal: Neuro-Oncology (2019)

Abstract High-grade gliomas are deadly cancers, and current standard-of-care has demonstrated limited success. The ability to specifically target glioma cells allows for the development of safer and more efficacious brain cancer therapy strategies. Brevican, a CNS-specific extracellular matrix protein is upregulated in glioma cells and its expression correlates with tumor progression. Particularly, a brevican isoform lacking glycosylation, B/bΔg is a unique glioma marker and not expressed in non-cancerous tissues. Therefore, B/bΔg represents a valuable target for anti-cancer strategies. Here, we describe the utilization of state-of-the-art platforms to screen a one-bead-one-compound combinatorial peptide library to discover a novel “B/bΔg-Targeting Peptides”, called BTP-7 that can bind B/bΔg with high affinity and specificity. BTP-7 displayed 260 nanomolar affinity for recombinant B/bΔg protein. Binding to a specific site on B/bΔg was confirmed in a competitive binding assay using BTP-7 functionalized with a UV-crosslinker and BTP-7 had little association with the fully glycosylated isoform of brevican (control). Scrambling of the BTP-7 sequence led to complete abrogation of B/bΔg binding. Furthermore, BTP-7 is preferentially taken up by B/bΔg-expressing glioma cells compared with non-expressing cells. We also discovered that BTP-7 can cross the blood-brain barrier in both the in vitro BBB organoid model and in mice. BTP-7 displayed 10x greater binding to intracranial GBM-6 tumors than control peptides, and 4x higher tumor uptake than in normal brain tissues. Conjugation of BTP-7 to camptothecin (an anti-tumor drug) via a cleavable linker led to increased DNA damage in intracranial GBM-6 tumors and prolonged survival in tumor-bearing mice. Our results show the potential of BTP-7 for the development of next-generation targeted therapeutics that could greatly benefit the outcome of patients with advanced brain cancer.
CSIG-19. CYTOMEGALOVIRUS INFECTION LEADS TO NF-kB DEPENDENT UPREGULATION OF c-MET AND MGMT IN GLIOBLASTOMA AND RESISTANCE TO TEMOZOLOMIDE IN VIVO
Authors: Mykola Zdioruk, Harald Krenzlin, M Oskar Nowicki, Charles H Cook, Ennio Chiocca, Sean Lawler
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Cytomegalovirus (CMV), a member of the betaherpesvirinae subfamily widespread in human populations has been reported to be detectable in glioblastoma (GBM). We have recently shown that CMV latent infection promotes GBM growth in a mouse model. The mechanisms involved are not well-defined and treatment responses have not been evaluated. METHODS To investigate the effects of CMV on GBM cells we performed an RNAseq study. Differentially expressed genes were identified and validated in vitro and in vivo. RESULTS RNAseq analysis showed multiple alterations induced by CMV infection of GBM cells including significant upregulation of c-MET (8.2 log2 fold change) and MGMT (3.9 log2 fold change) transcripts after CMV infection. c-MET is a tyrosine kinase receptor known to promote GBM growth, and MGMT expression leads to resistance to the alkylating agent temozolomide (TMZ). These findings were validated in vitro in both mouse and human GBM cells, and shown to be dependent on CMV-induced upregulation of NF-kB by siRNA knockdown of the essential RelA NF-kB subunit. The c-MET co-receptor CD44 was also upregulated suggesting a role for the c-MET signalling axis in CMV induced tumor progression. CMV-infected tumor cells were resistant to TMZ treatment as expected due to MGMT upregulation. Treatment of our murine GBM model with TMZ led to a significant increase in survival in control mock-infected mice (median survival 38 days control, 48 days TMZ), whereas the CMV infected mice did not respond (median survival 35 days control, 35 days TMZ; p value between TMZ treated groups = 10–4). CONCLUSIONS Our results define novel and relevant mechanisms by which CMV may influence both GBM growth and resistance to treatment. Further therapeutic and mechanistic studies are underway to investigate these pathways in the context of CMV in GBM. These data support further study of CMV targeting in GBM.
Mapping the Evolution of the Mutational Landscape of Acute Myeloid Leukemia from Diagnosis to Post-Transplantation Relapse and Its Interplay with Immune Evasion Mechanisms
Authors: Elisa Sala, Francesca Biavasco, Gabriele Bucci, Cristina Toffalori, Donatella Biancolini, Elena Antonini, Matteo Giovanni Carrabba, Bernhard Gentner, Cristina Tresoldi, Massimo Bernardi, Dejan Lazarevic, Giovanni Tonon, Fabio Ciceri, Luca Vago
Journal: Blood (2019)
Daratumumab Monotherapy in Previously Untreated High-Risk Patients with Stage 3B Light Chain (AL) Amyloidosis: A Phase II Multicenter Study By European Myeloma Network (EMN)
Authors: Eftathios Kastritis, Monique C. Minnema, Meletios A. Dimopoulos, Giampaolo Merlini, Pieter Sonneveld, Giovanni Palladini
Journal: Blood (2019)
Multicentre Genome Wide Association Study Identifies Risk Alleles for Progressive Chronic Lymphocytic Leukaemia
Authors: David Allsup, Wei Yu Lin, Sarah Elizabeth Fordham, Nicola Sunter, Claire Elstob, Thahira Rahman, Elaine Willmore, Colin Shepherd, Gordon Strathdee, Timothy Barrow, Tryfonia Mainou-Fowler, Rachel Piddock, Helen Marr, Jonathan Wallis, Scott R. Marshall, Geoffery Summerfield, Andrew Pettitt, Chris Pepper, Christopher Fegan, Francesco Forconi, Martin J.S. Dyer, Sandrine Jayne, April Sellors, Anna Schuh, Pauline Robbe, David Oscier, Richard S. Houlston, James Bailey, Syed Ashar Rais, Alison Bentley, Lynn Cawkwell, Peter Hillmen, Guy Pratt, James M. Allan
Journal: Blood (2019)
Abstract 14980: Chronic E-cigarette Users Demonstrate More Persistent Coronary Endothelial Dysfunction Than Chronic Combustible Cigarette Users
Authors: Mohamad Rashid, Katherine Davoren, Norma B Moy, Fida Nafeh, Robert Elashoff, Chulkyu Kim, Andy Kim, Elizabeth Kim, Michael D Nelson, Susan Cheng, Florian Rader
Journal: Circulation (2019)

Background: Electronic (e-) cigarettes are marketed as a safer alternative to tobacco, given the lower dose of nicotine delivered per inhalation. However, e-cigarettes also deliver an aerosolized b...
Percentage of Infiltrating T Lymphocytes in Diffuse Large B-Cell Lymphoma Lymph Nodes Measured By Flow Cytometry Predicts Overall Survival and Provides Additional Prognostic Information When Combined with the R-IPI
Authors: Laura Korin, Maria Del Rosario Custidiano, Maria Lucia Fuente, Santiago Cranco, Adriana Vitriu, Paola Ochoa, Evelina Babuin, Fernando Diaz Couselo, Anahí Vijnovich Baron, Paula Tempra, Maria Belen Venegas, Andrea Novoa, Norma Elisabeth Tartas, Maria Cecilia Foncuberta, Julio Cesar Sanchez Avalos
Journal: Blood (2019)
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
Authors: Thomas Powles, Mark Kockx, Alejo Rodriguez-Vida, Ignacio Duran, Simon J. Crabb, Michiel S. Van Der Heijden, Bernadett Szabados, Albert Font Pous, Gwenaelle Gravis, Urbano Anido Herranz, Andrew Protheroe, Alain Ravaud, Denis Maillet, Maria Jose Mendez, Cristina Suarez, Mark Linch, Aaron Prendergast, Pieter-Jan van Dam, Diana Stanoeva, Sofie Daelemans, Sanjeev Mariathasan, Joy S. Tea, Kelly Mousa, Romain Banchereau, Daniel Castellano
Journal: Nature Medicine (2019)
Risk Factors and the Therapeutic Efficacy for Thrombotic Microangiopathy in Patients after Allogeneic Hematopoietic Stem Cell Transplantation - Results of the Multicenter Retrospective Cohort Study
Authors: Hiroharu Imoto, Hiroyuki Matsui, Yasuyuki Arai, Tadakazu Kondo, Yasunori Ueda, Kazunori Imada, Takashi Akasaka, Akihito Yonezawa, Kazuhiro Yago, Takayuki Ishikawa, Akifumi Takaori-Kondo
Journal: Blood (2019)
SCIDOT-03. HYPERLOADED POLY(2-OXAZOLINE) MICELLES AS PERSONALIZED DRUG CARRIERS FOR BRAIN TUMORS
Authors: Duhyeong Hwang, Taylor Dismuke, Elias Rosen, John Kagel, Chaemin Lim, William Zamboni, Alexander Kabanov, Timothy Gershon, Marina Sokolsky-Papkov
Journal: Neuro-Oncology (2019)

Abstract Systemic therapies for brain tumors are complicated by dose-limiting extraneural toxicity, serum protein binding and restricted blood-brain barrier (BBB) permeability. For patients with SHH-subgroup medulloblastoma, SHH-pathway inhibition may be more effective and less toxic than current non-targeted therapy. However, vismodegib, which effectively targets SHH-driven basal cell carcinoma, has limited benefit for patients with SHH-driven medulloblastoma. Formulating vismodegib in poly(2-oxazoline) micelles (POx-vismo) improved delivery and efficacy, using medulloblastoma-prone hGFAP-Cre/SmoM2 (G-Smo) mice for a preclinical model. Compared to conventional vismodegib (c-vismo), POx-vismo increased maximum tolerated dose (MTD), tumor:serum ratio and penetration to brain and tumor. Further studies have shown the ability of POx micelles to load CDK4/6 inhibitor. Loading into POx micelles improved MTD and efficacy of palbociclib. Taken together, our results show the potential for poly(2-oxazoline) micelles delivery to make failed brain tumor treatments newly effective. This work was supported by the NCI Alliance for Nanotechnology in Cancer (U54CA198999, Carolina Center of Cancer Nanotechnology Excellence), by NINDS (R01NS088219, R01NS102627) and by the St. Baldrick’s Foundation. References: 1 H. Bader et al. Angew. Macromol. Chem. 1984, 123/124:457; A. Kabanov et al. FEBS Lett. 1989, 258:343; M. Yokoyama et al. Cancer Res. 1990, 50:1693. 2 M. Yokoyama et al. J. Exp. Clin. Med. 2011, 3:8. 3 T. Lorson et al. Biomaterials. 2018, 178:204. 4 R. Luxenhofer et al. Biomaterials 2010, 31:4972; A. Schulz et al. ACS Nano 2014, 8 (3):2686; Z. He et al. Biomaterials 2016, 101:296
CHRONIC AURICULAR FLUTTER
Authors: N M FENICHEL
Journal: Annals of Internal Medicine (1948)

Case Reports1 July 1948CHRONIC AURICULAR FLUTTERNATHAN M. FENICHEL, M.D., F.A.C.P.NATHAN M. FENICHEL, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-29-1-144 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptDuring the past three years, three cases of auricular flutter in which the arrhythmia has persisted for prolonged periods have been seen. This is an occurrence at some variance with the general belief that auricular flutter is of short duration, a few weeks at most, and that its circus movement soon changes to either auricular fibrillation or else ceases with the resumption of normal sinus rhythm.In the first patient, auricular flutter is still present after three years despite several attempts at interruption of the circus movement. In the second patient, the flutter remained for 15 months until his death...Bibliography1. WHITE PD: Heart disease, 1944, The Macmillan Co., New York, p. 903. Google Scholar2. SPRAGUEWHITE HBPD: Auricular flutter. Report of a case of five years' duration with spontaneous restoration of normal rhythm, Jr. Am. Med. Assoc., 1928, xc, 1772. CrossrefGoogle Scholar3. LEWIS T: Auricular flutter continuing for 24 years, British Med. Jr., 1937, i, 1248. CrossrefGoogle Scholar4. KOSSMANBERGER CEAR: Auricular flutter of eleven years' duration with observations on esophageal electrocardiograms, Ann. Int. Med., 1941, xv, 128. Google Scholar5. WHITE PD: Heart disease, 1944, The Macmillan Co., New York, p. 906. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Brooklyn, N. Y.*Received for publication June 18, 1947.From the Medical Divisions of the Jewish Hospital and the Kings County Hospital, Brooklyn, New York. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAURICULAR FLUTTER WITH COMPLETE HEART BLOCK: "SADDLE EMBOLUS" IN A CASE OF RHEUMATIC VALVULAR DISEASE*OSCAR H. COMESS, M.D.AURICULAR FLUTTER WITH COMPLETE HEART BLOCK*OTTO BRANDMAN, M.D., WILLIAM J. MESSINGER, M.D., WALTER REDISCH, M.D., F.A.C.P., KURT ZELTMACHER, M.D. 1 July 1948Volume 29, Issue 1Page: 144-151KeywordsArrhythmiaAtrial fibrillation ePublished: 1 December 2008 Issue Published: 1 July 1948 PDF downloadLoading ...
R-m-NHL-BFM-90/R-EPOCH Protocol in the Treatment of Patients with Primary Mediastinal Lymphoma: First Results
Authors: Nelly G Gabeeva, Darya A Koroleva, Svetlana A Tatarnikova, Anna K Smolyaninova, Svetlana Smirnova, Elena E Nikulina, Alla M. Kovrigina, Andrey B Sudarikov, Eugene E. Zvonkov, Valery G. Savchenko
Journal: Blood (2019)